Unfortunately, one of the two patients with increased sPAP at follow-up refused the RHC, which may not have confirmed the presence of a PAH, reinforcing the hypothesis that the combo therapy could prevent PAH development. Here, PDZK1IP1 is linked to pulmonary arterial hypertension.